245 related articles for article (PubMed ID: 30022385)
61. Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
Koyama N; Watanabe Y; Iwai Y; Kawamura R; Miwa C; Nagai Y; Hagiwara K; Koyama S
Chemotherapy; 2017; 62(3):151-158. PubMed ID: 28110331
[TBL] [Abstract][Full Text] [Related]
62. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
63. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
[TBL] [Abstract][Full Text] [Related]
64. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Yang H; He D; Wang F; Deng Q; Xie Z
Clin Exp Metastasis; 2020 Jun; 37(3):391-399. PubMed ID: 32356218
[TBL] [Abstract][Full Text] [Related]
65. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
66. The Frequency and Specific Features of Rare Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma whose Tumors harbor positive EGFR mutations.
El Yacoubi H; Lemine Sow M; El Ghouti M; Kettani F; Gamra L; Mestari A; Jabri L; Elghissassi I; Errihani H
Gulf J Oncolog; 2020 May; 1(33):40-44. PubMed ID: 32476648
[TBL] [Abstract][Full Text] [Related]
67. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
[TBL] [Abstract][Full Text] [Related]
68. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.
Tseng JS; Yang TY; Tsai CR; Chen KC; Hsu KH; Tsai MH; Yu SL; Su KY; Chen JJ; Chang GC
J Thorac Oncol; 2015 Apr; 10(4):603-10. PubMed ID: 25514801
[TBL] [Abstract][Full Text] [Related]
69. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
[TBL] [Abstract][Full Text] [Related]
70. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.
Lee YJ; Park IK; Park MS; Choi HJ; Cho BC; Chung KY; Kim SK; Chang J; Moon JW; Kim H; Choi SH; Kim JH
J Cancer Res Clin Oncol; 2009 Dec; 135(12):1647-54. PubMed ID: 19517135
[TBL] [Abstract][Full Text] [Related]
71. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
[TBL] [Abstract][Full Text] [Related]
72. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.
Yoon HY; Ryu JS; Sim YS; Kim D; Lee SY; Choi J; Park S; Ryu YJ; Lee JH; Chang JH
PLoS One; 2020; 15(2):e0228925. PubMed ID: 32053675
[TBL] [Abstract][Full Text] [Related]
73. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Yoshiya T; Kai Y; Tsutani Y; Mimura T; Konishi K; Takeshima Y; Okada M
Thorac Cancer; 2018 Dec; 9(12):1594-1602. PubMed ID: 30298562
[TBL] [Abstract][Full Text] [Related]
74. Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases.
Inoue T; Matsumura Y; Araki O; Karube Y; Maeda S; Kobayashi S; Chida M
Ann Thorac Cardiovasc Surg; 2018 Feb; 24(1):1-5. PubMed ID: 29093430
[TBL] [Abstract][Full Text] [Related]
75. Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Yang X; Dong X; Wang J; Li W; Gu Z; Gao D; Zhong N; Guan Y
Oncologist; 2019 Nov; 24(11):e1156-e1164. PubMed ID: 30936378
[TBL] [Abstract][Full Text] [Related]
76. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities.
Liu M; He WX; Song N; Yang Y; Zhang P; Jiang GN
Eur J Cardiothorac Surg; 2016 Nov; 50(5):909-913. PubMed ID: 27032467
[TBL] [Abstract][Full Text] [Related]
77. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
[TBL] [Abstract][Full Text] [Related]
78. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa S; Zenke Y; Taki T; Aokage K; Sakai T; Shibata Y; Izumi H; Nosaki K; Umemura S; Matsumoto S; Yoh K; Sakamoto N; Sakashita S; Kojima M; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2024 Feb; 188():107453. PubMed ID: 38160515
[TBL] [Abstract][Full Text] [Related]
79. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
Yotsukura M; Yasuda H; Shigenobu T; Kaseda K; Masai K; Hayashi Y; Hishida T; Ohtsuka T; Naoki K; Soejima K; Betsuyaku T; Asamura H
Lung Cancer; 2017 Jul; 109():45-51. PubMed ID: 28577949
[TBL] [Abstract][Full Text] [Related]
80. Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.
Peng M; Weng YM; Liu HL; Yang GF; Yao Y; Han G; Song QB
Biomed Res Int; 2018; 2018():7181368. PubMed ID: 29581983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]